Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones